UroGen Pharma Ltd. (URGN) Stock Analysis
A live, multi-source view of UroGen Pharma Ltd. (URGN): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 300 employees · urogen.com
Key statistics · as of 2026-09-06
As of 2026-09-06, UroGen Pharma Ltd. (URGN) had a market capitalization of $2.16B (forward 15.8) and a beta of 1.58; the shares traded in a 52-week range of $15.86 – $50.81 (105.8% over the year).
- Market cap
- $2.16B
- Enterprise value
- $2.24B
- Forward P/E
- 15.8
- EPS (trailing)
- $-1.97
- EPS (forward)
- $2.79
- Payout ratio
- 0.0%
- 52-week range
- $15.86 – $50.81
- 52-week change
- 105.8%
- Beta
- 1.58
- Average volume
- 815,952
- Shares outstanding
- 48.9M
- Short % of float
- 10.69%
- Profit margin
- -51.7%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, UroGen Pharma Ltd. (URGN) last closed at $42.24 (the last completed close before that scan).
Technicals at the scan: RSI 42 (neutral territory), price -7.9% versus its 20-day average, 20-day versus 50-day average spread +6.3%, MACD histogram -0.57.
Sentiment inputs: 75% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of URGN; corporate insiders filed 0 buys and 3 sells (2 distinct filers, latest disclosure 2026-09-09). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Mark Schoenberg (0B/2S), Jason Drew Smith (0B/1S). Who is trading what
RapidTradeView pick record
URGN has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls UroGen Pharma Ltd. (URGN) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell URGN.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.